DO-2

DeuterOncology’s lead product DO-2 is an improved MET kinase inhibitor, which is being developed as a potential ‘best in class’ targeted therapy for lung cancer.

The metabolically labile hydrogen has been replaced with a stronger bond strength deuterium atom that significantly reduces the importance of this metabolic liability.  In addition, the formation of an active metabolite has been shown, that maintains activity on the MET kinase as well as binding to an alternative kinase that is a constituent of the ras pathway.

DeuterOncology has initiated the Phase 1 clinical study in Q4 2022 to validate DO-2 as a ‘Best in Class’ MET kinase inhibitor as well as to identify a recommended phase 2 dose. The clinical study (EudraCT 2022-001681-35) is open for recruitment at three trial sites in Belgium (Prof Jean-Pascal Machiels (jean-pascal.machiels@saintluc.uclouvain.be), and Dr Rachel Galot (rachel.galot@saintluc.uclouvain.be), Cliniques universitaires Saint-Luc, UCLouvain Brussels; Prof Hans Prenen (Hans.Prenen@uza.be), UZA Antwerp) and Prof Sylvie Rottey (sylvie.rottey@ugent.be) : two sites in the Netherlands (Dr Debbie Robbrecht (d.robbrecht@erasmusmc.nl), Erasmus MC Rotterdam) and Prof Carla van Herpen (Carla.vanHerpen@radboudumc.nl) Radboud University Medical Center, Dept. of Medical Oncology, Nijmegen and three sites in France Prof Alexis Cortot (alexis.cortot@chu-lille.fr) Institut Cœur Poumon, CHU Lille : Dr Aurélie Swalduz (aurelie.swalduz@lyon.unicancer.fr) Centre Leon Berard, Dept. of Medical Oncology, Lyon: Prof Francois Ghiringelli (fghiringhelli@cgfl.fr) Centre Georges Francois Leclerc, Department of Medical Oncology, Dijon